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ABSTRACT
Metformin is recommended as a first-line
therapy for patients with type 2 diabetes
mellitus (T2DM). However, many patients do
not achieve glycemic goals with metformin
monotherapy and require subsequent
combination therapy with other
antihyperglycemic agents (AHAs). For newly
diagnosed patients with high blood glucose,
initial combination therapy may be required to
achieve glycemic control. The American
Association for Clinical Endocrinologists
algorithm for the treatment of T2DM
recommends metformin plus a sodium glucose
co-transporter 2 (SGLT2) inhibitor as the first
oral combination in patients who present with
HbA1c C7.5%. Canagliflozin, an SGLT2
inhibitor, lowers the renal threshold for
glucose and increases urinary glucose
excretion leading to a mild osmotic diuresis
and a net caloric loss. The effect of canagliflozin
is insulin-independent and complementary to
other AHAs, including metformin. A fixed-dose
combination (FDC) of canagliflozin and
metformin is also available with variable
dosing, which may be attractive to some
patients owing to the potential for reduced pill
burden and costs. This article reviews the
efficacy and safety of canagliflozin in
combination with metformin based on data
from the canagliflozin phase 3 clinical program.
As initial combination therapy in drug-naı¨ve
patients or as dual therapy with metformin or
triple therapy in combination with metformin
and other AHAs, canagliflozin 100 and 300 mg
improved glycemic control and provided
reductions in body weight and systolic blood
pressure that were sustained for up to
104 weeks. Canagliflozin was generally well
tolerated across studies in combination with
metformin. An increased incidence of adverse
events (AEs) related to the mechanism of SGLT2
inhibition (i.e., genital mycotic infections,
urinary tract infections, osmotic
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diuresis-related AEs) was observed with
canagliflozin. Canagliflozin was associated
with a low incidence of hypoglycemia when
not used in conjunction with AHAs associated
with hypoglycemia (i.e., insulin or
sulfonylurea). Together, these results support
the use of a canagliflozin and metformin FDC as
a treatment approach for a broad range of
patients with T2DM.
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INTRODUCTION
Clinical practice guidelines recommend
metformin as a first-line pharmacologic
therapy for the management of type 2 diabetes
mellitus (T2DM) [1–3]. Metformin works by
decreasing hepatic glucose production and
intestinal glucose absorption and by
improving insulin sensitivity, thereby
enhancing peripheral glucose uptake [4, 5].
Enhanced excretion of glucagon-like peptide-1
with metformin may contribute to the
intestinal glucose-lowering activity [6, 7].
Metformin may not be tolerated in all patients
because of gastrointestinal side effects [8, 9].
Due to the progressive nature of T2DM, most
patients eventually require combination
therapy with other antihyperglycemic agents
(AHAs) [2, 10, 11]. In addition, many patients
can receive initial combination therapy at the
time of diabetes diagnosis in order to reach
glycemic goals efficiently. The guidelines
related to the use of combination therapy vary
among national and regional organizations. For
example, the American Diabetes Association
supports initiation of dual therapy in newly
diagnosed patients with T2DM and HbA1c
C9.0% [2]. The American Association of
Clinical Endocrinologists (AACE) takes a more
aggressive approach, recommending initial
combination therapy for patients with HbA1c
C7.5% [1]. The Texas Diabetes Council gives an
option for initiation of monotherapy in
patients who present with HbA1c \1% above
their individualized goal; in patients with
HbA1c [1.0% above their goal, initial
combination therapy is recommended [12].
Sodium glucose co-transporter 2 (SGLT2)
inhibitors are recommended by AACE as the
first oral add-on for patients inadequately
controlled on metformin [1]. Canagliflozin, an
SGLT2 inhibitor, lowers plasma glucose levels in
patients with T2DM by increasing urinary
glucose excretion, resulting in a mild osmotic
diuresis and a net caloric loss [13]. This
insulin-independent mechanism of action is
complementary to other types of AHAs,
including metformin [2]. Across phase 3 trials,
as monotherapy or in combination with
metformin or other AHAs, canagliflozin 100
and 300 mg have been shown to provide not
only glycemic improvement but also weight loss
andbloodpressure (BP) lowering in a broad range
of patients with T2DM [14]. An oral fixed-dose
combination (FDC) tablet of canagliflozin and
metformin immediate release (IR) was approved
in 2014 for the treatment of adults with T2DM
[15], and findings from a study of initial
combination therapy with canagliflozin plus
metformin extended release (XR) have recently
been published [16]. This review summarizes the
clinical data in support of the canagliflozin and
metformin FDC. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
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CANAGLIFLOZIN ANDMETFORMIN
FDC
The canagliflozin and metformin IR FDC is
indicated as an adjunct to diet and exercise to
improve glycemic control in adults with T2DM.
The canagliflozin and metformin IR FDC
formulation is available in four dose strengths
(50/500 mg, 50/1000 mg, 150/500 mg,
150/1000 mg) and should be taken twice daily
with food [15]. Gradual dose escalation of
metformin is recommended to limit
gastrointestinal side effects associated with
metformin. The twice-daily dose of
canagliflozin should not exceed 150 mg (total
daily dose [TDD] of 300 mg), and canagliflozin
should be restricted to 50 mg twice daily (TDD
of 100 mg) for patients with estimated
glomerular filtration rate (eGFR) C45 to
\60 mL/min/1.73 m2 [15]. An oral FDC
containing immediate-release canagliflozin
and metformin XR in a bilayer tablet
formulation was recently approved in the USA
[17]; the XR FDC formulation was under
development during the writing of this article




Findings from phase 1 pharmacokinetic,
bioequivalence, and food-effect studies of
canagliflozin have confirmed that there are no
clinically relevant differences between
single-pill FDCs of canagliflozin and
metformin IR compared with concomitant
administration of the individual components
[18, 19]. Phase 1 pharmacodynamic study
results have also shown that there are no
clinically meaningful differences between the
once-daily canagliflozin dosing used in the
phase 3 program, which is approved as a
single-component formulation [20], and the
same TDD administered twice daily, which is
used in the FDC with metformin IR [15, 21]. No
safety differences have been observed between
the FDC of canagliflozin and metformin IR and
coadministration of the individual components
[18, 19], or between once-daily vs twice-daily
dosing of canagliflozin [21]. Efficacy results
from a dose-ranging phase 2 study of
canagliflozin as add-on to metformin
confirmed the dose selections of canagliflozin
100 and 300 mg used in the phase 3 program
[22]. A subsequent phase 2 study established
that twice-daily treatment with canagliflozin
(50 or 150 mg) in patients with T2DM
inadequately controlled with metformin
monotherapy was comparable to results
observed in phase 3 studies of once-daily






Canagliflozin has been evaluated in an
extensive clinical development program, but
no phase 3 clinical trials have been conducted
on the canagliflozin/metformin FDC. The
efficacy and safety of the canagliflozin/
metformin FDC is supported by data from six
phase 3 studies or substudies of once-daily
canagliflozin 100 or 300 mg in patients with
T2DM as add-on to metformin with or without
other AHAs, and a phase 3 initial combination
therapy study of canagliflozin plus metformin
XR, which also evaluated canagliflozin versus
metformin monotherapy (Table 1) [16, 24–30].
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Table 1 Study design and patient populations of phase 3 studies of canagliﬂozin in combination with metformin ± other
AHAs in patients with T2DM [16, 24–30]
















(not on AHA therapy
or off for C12 weeks
before screening)
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300 mg/MET,
n = 237; CANA
100 mg, n = 237;
CANA 300 mg,
n = 238; MET,
n = 237














[or C1500 mg/day if
unable to tolerate a
higher dose]) for
C8 weeks
N = 1284; PBO/SITA,
n = 183; SITA
100 mg, n = 366;
CANA 100 mg,
n = 368; CANA
300 mg, n = 367

















N = 1450; GLIM,
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[or C1500 mg/day if
unable to tolerate a
higher dose]) and SU
(at least half of
maximally labeled
dose) for C8 weeks
N = 755; CANA

















[or C1500 mg/day if
unable to tolerate a
higher dose]) and SU
(at least half of
maximally labeled
dose) for C8 weeks
N = 469, PBO,
n = 156; CANA
100 mg, n = 157;
CANA 300 mg,
n = 156
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Key efficacy analyses in these studies included
changes from baseline in HbA1c, body weight,
and systolic BP (Tables 2, 3, 4); safety and
tolerability were assessed on the basis of
adverse event (AE) reports.
Efficacy
Initial Combination Therapy
with Canagliflozin and Metformin
A 26-week initial combination therapy study
assessed the efficacy and safety of canagliflozin
and metformin XR versus canagliflozin or
metformin monotherapy in drug-naı¨ve
patients [16]. Greater reductions in HbA1c
were seen with canagliflozin 100 mg/
metformin and canagliflozin 300 mg/
metformin compared with metformin alone at
26 weeks (-1.77%, -1.78%, and -1.30%,
respectively; P = 0.001 for both comparisons;
Table 2). Canagliflozin 100 and 300 mg
monotherapy were noninferior in HbA1c
lowering compared with metformin (-1.37%,
-1.42%, and -1.30%, respectively). A greater
proportion of patients achieved HbA1c\7.0%
with both canagliflozin 100 mg/metformin and
canagliflozin 300 mg/metformin than
metformin alone at week 26 (49.6, 56.8, and
43.0%, respectively; P = 0.027 for canagliflozin
100 mg/metformin vs metformin and P = 0.016
for canagliflozin 300 mg/metformin vs
metformin). Canagliflozin 100 mg/metformin
Table 1 continued
Study Study design Key inclusion criteria Background therapy Patients
Add-on to














[or C1500 mg/day if
unable to tolerate a
higher dose]) and PIO
30 or 45 mg/day for
C8 weeks
N = 342; PBO/SITA,
n = 115; CANA





























N = 432; PBO,
n = 145; CANA
100 mg, n = 139;
CANA 300 mg,
n = 148
AHA antihyperglycemic agent, T2DM type 2 diabetes mellitus, CANA canagliﬂozin, MET metformin, eGFR estimated
glomerular ﬁltration rate, PBO placebo, SITA sitagliptin, GLIM glimepiride, SU sulfonylurea, PIO pioglitazone, CANVAS
CANagliﬂozin cardioVascular Assessment Study
* The required eGFR was C60 mL/min/1.73 m2 if based on restriction of metformin use in the local label
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and canagliflozin 300 mg/metformin provided
greater body weight reductions compared with
metformin alone (-3.5%, -4.2%, and -2.1%;
P = 0.001 for both comparisons; Table 3).
Reductions in systolic BP were numerically
greater with canagliflozin 100 mg/metformin
and canagliflozin 300 mg/metformin
compared with metformin alone (-2.2, -1.7,
and -0.3 mmHg, respectively; Table 4).
Canagliflozin as Dual Therapy
with Metformin
A 52-week study assessed the efficacy and safety
of canagliflozin 100 and 300 mg versus placebo
at week 26 and versus sitagliptin 100 mg as
add-on to metformin [24]. Reductions in HbA1c
at week 26 were greater with canagliflozin 100
and 300 mg compared with placebo (-0.79%,
-0.94%, and -0.17%, respectively; P\0.001
for both comparisons; Table 2). At week 52,
canagliflozin 100 mg was noninferior and
canagliflozin 300 mg was statistically superior
to sitagliptin 100 mg in HbA1c lowering
(-0.73%, -0.88%, and -0.73%, respectively;
Table 2). A greater proportion of patients
achieved HbA1c\7.0% with canagliflozin 100
and 300 mg compared to placebo at week 26
(46%, 58%, and 30%, respectively) and
compared with sitagliptin 100 mg at week 52
(55%, 41%, and 51%, respectively).
Canagliflozin 100 and 300 mg significantly
reduced body weight compared with placebo
(-3.7%, -4.2%, and -1.2%, respectively;
P\0.001 for both comparisons; Table 3) at
week 26. Greater reductions in body weight
were seen with canagliflozin 100 and 300 mg
versus sitagliptin 100 mg at week 52 (-3.8%,
-4.2%, and -1.3%, respectively; P\0.001 for
both comparisons; Table 3). At week 26, systolic
BP reductions were seen with canagliflozin 100
and 300 mg (-3.8 and -5.1 mmHg,
respectively) compared with an increase of
1.5 mmHg with placebo (P\0.001 for both
comparisons; Table 4). At week 52, reductions
in systolic BP were larger with canagliflozin 100
and 300 mg compared with sitagliptin 100 mg
(-3.5, -4.7, and -0.7 mmHg, respectively;
P\0.001 for both comparisons; Table 4).
A 104-week study assessed the efficacy and
safety of canagliflozin 100 and 300 mg versus
glimepiride as add-on to metformin at weeks 52
and 104 [25, 30]. At week 52, canagliflozin
100 mg demonstrated noninferiority and
canagliflozin 300 mg demonstrated superiority
in HbA1c lowering compared with glimepiride
(-0.82%, -0.93%, and -0.81%, respectively;
Table 2) [25]. Reductions in HbA1c were
sustained at week 104 (-0.65%, -0.74%, and
-0.55%, respectively; Table 2) [30]. At week 52,
54, 60, and 56% of patients achieved HbA1c
\7.0% with canagliflozin 100 and 300 mg and
glimepiride, respectively [25]. At week 104, 43,
50, and 44% of patients achieved HbA1c\7.0%,
respectively [30]. Body weight at week 52 was
significantly reduced with canagliflozin 100 and
300 mg (-4.2% and -4.7%, respectively),
compared with a 1.0% increase with
glimepiride (P\0.0001 for both comparisons;
Table 3) [25]. Reductions in body weight with
canagliflozin 100 and 300 mg versus
glimepiride were maintained at week 104
(-4.1%, -4.2%, and 0.9%, respectively;
Table 3) [30]. Reductions in systolic BP were
seen with canagliflozin 100 and 300 mg (-3.3
and -4.6 mmHg) compared to an increase of
0.2 mmHg with glimepiride at 52 weeks
(Table 4) [25]. At week 104, changes in systolic
BP were -2.0, -3.1, and 1.7 mmHg, respectively
(Table 4) [30].
Canagliflozin in Combination with Metformin
Plus Other AHAs
A 52-week study evaluated the efficacy and
safety of canagliflozin 300 mg versus sitagliptin
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100 mg as add-on to metformin plus
sulfonylurea [28]. Canagliflozin 300 mg
demonstrated superiority in HbA1c lowering
versus sitagliptin 100 mg at week 52 (-1.03%
and -0.66%, respectively; Table 2). The greater
HbA1c lowering with canagliflozin 300 mg was
accompanied by a greater proportion of patients
achieving HbA1c \7.0% with canagliflozin
300 mg versus sitagliptin 100 mg (48% vs
35%). Canagliflozin 300 mg significantly
reduced body weight compared to sitagliptin
100 mg (-2.5% vs 0.3%; P\0.001; Table 3).
Canagliflozin 300 mg also significantly reduced
systolic BP (-5.1 mmHg) versus an increase of
0.9 mmHg with sitagliptin 100 mg (P\0.001;
Table 4).
A placebo-controlled study evaluated the
efficacy and safety of canagliflozin 100 and
300 mg as add-on to metformin plus
sulfonylurea at weeks 26 and 52 [27].
Canagliflozin 100 and 300 mg provided greater
reductions in HbA1c compared with placebo at
week 26 (-0.85%, -1.06%, and -0.13%,
respectively; P\0.001 for both comparisons);
these reductions were maintained at week 52
(-0.74%, -0.96%, and 0.01%, respectively;
Table 2). A greater proportion of patients
receiving canagliflozin 100 and 300 mg
achieved HbA1c\7.0% at week 26 than those
receiving placebo (43, 57, and 18%,
respectively; P\0.001 for both comparisons).
At week 52, 39, 53, and 19% of patients
achieved HbA1c\7.0% with canagliflozin 100
and 300 mg and placebo, respectively.
Significant body weight reductions were seen
with canagliflozin 100 and 300 mg compared
with placebo at week 26 (-2.1%, -2.6%, and
-0.7%, respectively; P\0.001 for both
comparisons) and were sustained at week 52
(-2.2%, -3.2%, and -0.9%, respectively;
Table 3). Canagliflozin 100 and 300 mg
provided numerically greater reductions in
systolic BP compared with placebo at week 26
(-4.9, -4.3, and -2.7 mmHg, respectively);
changes in systolic BP were -3.7, -2.9, and
0.1 mmHg, respectively, at week 52 (Table 4).
In a study as add-on to metformin plus
pioglitazone, the efficacy and safety of
canagliflozin 100 and 300 mg were assessed
versus placebo at week 26 [26]. The study
included a 26-week extension during which
patients receiving placebo were switched to
sitagliptin 100 mg; this arm was not included
in efficacy evaluations at week 52. At week 26,
greater reductions in HbA1c were seen with
canagliflozin 100 and 300 mg versus placebo
(-0.89%, -1.03%, and -0.26%, respectively;
P\0.001 for both comparisons; Table 2). A
greater proportion of patients achieved HbA1c
\7.0% with canagliflozin 100 and 300 mg
versus placebo (47, 64, and 33%, respectively).
Reductions in body weight were greater with
canagliflozin 100 and 300 mg compared with
placebo at week 26 (-2.8%, -3.8%, and -0.1%,
respectively; P\0.001 for both comparisons;
Table 3). Similarly, canagliflozin 100 and
300 mg provided larger reductions in systolic
BP compared with placebo (-5.3, -4.7, and
-1.2 mmHg, respectively; Table 4). Reductions
in HbA1c, body weight, and systolic BP with
canagliflozin 100 and 300 mg were maintained
at week 52 (Tables 2, 3, 4).
In a prespecified analysis of a subset of
patients with either a history or high risk of
cardiovascular disease enrolled in the
CANagliflozin cardioVascular Assessment
Study (CANVAS) who were on background
metformin plus insulin, the efficacy and safety
of canagliflozin 100 and 300 mg were assessed
versus placebo at week 18 [29]. Canagliflozin
100 and 300 mg reduced HbA1c compared with
placebo (-0.64%, -0.79%, and 0.03%,
respectively; P\0.001 for both comparisons;
Table 2). A greater proportion of patients
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achieved HbA1c\7.0% with canagliflozin 100
and 300 mg versus placebo (19%, 29%, and 9%,
respectively; P = 0.008 for canagliflozin 100 mg
vs placebo; P\0.001 for canagliflozin 300 mg vs
placebo). Significant reductions in body weight
were seen with canagliflozin 100 and 300 mg
compared with placebo (-1.7%, -2.7%, and
0.0%, respectively; P\0.001 for both
comparisons; Table 3). Canagliflozin 100 and
300 mg provided larger reductions in systolic BP
compared with placebo (-5.2, -7.7, and
-1.7 mmHg, respectively; P\0.001 for
canagliflozin 300 mg vs placebo; Table 4).
Safety and Tolerability
Canagliflozin in combination with metformin
has been associated with a favorable safety and
tolerability profile across phase 3 studies
(Table 5) [16, 24–30]. Rates of AEs leading to
discontinuation and serious AEs were generally
low with canagliflozin versus comparators
[16, 24–30]. Not surprisingly, the incidence of
AEs related to SGLT2 inhibition (e.g., genital
mycotic infections, urinary tract infections,
osmotic diuresis-related AEs) was generally
higher with canagliflozin versus comparators
[16, 24–30]. Risk factors for genital mycotic
infection include a prior history of recurrent
genital mycotic infections and uncircumcision.
Older patients, those with reduced renal
function, those with reduced BP, and those
taking diuretics may be vulnerable to the
volume depletion effects of canagliflozin.
These patients, in particular, should be advised
to drink plenty of non-sugar-containing fluids,
and consideration should be given to reducing
or holding their diuretics until after they are
reassessed. Gastrointestinal intolerability is a
common side effect of metformin [9]; however,
the combination of canagliflozin and
metformin has not been associated with an
increased incidence of gastrointestinal-related
AEs (i.e., diarrhea, nausea, and vomiting) [31].
Reports of hypoglycemia have been generally
low with canagliflozin among patients not on
background therapy associated with
hypoglycemia (i.e., sulfonylurea or insulin)
and in patients treated with initial
canagliflozin/metformin combination therapy
[16, 24–30].
No serious AEs of diabetic ketoacidosis have
been seen with canagliflozin as add-on to
metformin alone or in combination with
pioglitazone, or in the subset of patients from
the CANVAS trial on background metformin
plus insulin [32]. There was one serious
ketoacidosis AE with canagliflozin 100 mg in
the placebo-controlled add-on to metformin
plus sulfonylurea study [27], and the patient
subsequently received a diagnosis of type 1
diabetes mellitus [32]. In the initial
combination study [16], there was one serious
AE of ketoacidosis in a patient in the
canagliflozin 300 mg group with confounding
factors that included acute infection, chronic
pancreatitis, and heart failure class II [32]. It is
important to note that patients with HbA1c
[10.5% were excluded from these studies.
The incidence of fractures was low and
similar with canagliflozin versus comparators
across the phase 3 program in non-CANVAS
studies, including those as add-on to metformin
with or without other AHAs [33].
Across studies, canagliflozin was generally
associated with reductions in triglycerides and
increases in both high-density lipoprotein
cholesterol and low-density lipoprotein
cholesterol [16, 24–30]. Changes in laboratory
parameters (i.e., alanine aminotransferase,
aspartate aminotransferase, bilirubin, blood
urea nitrogen, creatinine, urate, and
hemoglobin) with canagliflozin were not
clinically meaningful. Treatment with
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Table 5 Safety summary from phase 3 studies of canagliﬂozin in combination with metformin [16, 24–30]
Parameter Combination of CANA 1MET
Overall safety and tolerability Generally well tolerated; low incidence of AEs leading to study
discontinuation and serious AEs
Genital mycotic infections Higher incidence versus PBO, SITA, and GLIM; low incidence with
CANA/MET in initial combination therapy
Generally mild or moderate in intensity; few led to study discontinuation
Generally higher incidence in women than in men; more likely to occur
in patients with a history of genital mycotic infections and in
uncircumcised males
UTIs Low incidence across studies; higher incidence versus GLIM and PBO;
similar incidence compared with SITA
Generally mild to moderate in intensity and few led to discontinuation;
low incidence of serious or upper UTIs
Osmotic diuresis–related AEs (e.g., pollakiuria,
polyuria, thirst)
Generally low incidence
Higher incidence versus PBO, SITA, and GLIM; few led to study
discontinuation
Volume depletion–related AEs (e.g., orthostatic
hypotension, dizziness postural)
Generally low incidence; dose-dependent increase in incidence seen across
studies
Incidence was higher in patients taking loop diuretics, in patients with
moderate renal impairment (i.e., eGFR C30 to\60 mL/min/1.73 m2),
and in patients aged C75 years
Gastrointestinal-related AEs (i.e., diarrhea,
nausea, vomiting)
No increase in incidence with CANA as add-on to MET ± other AHAs
versus PBO, SITA, or GLIM; incidence was low with CANA/MET as
initial combination therapy
Hypoglycemia Low incidence when not used in combination with background AHAs
associated with hypoglycemia (e.g., SU or insulin)
Signiﬁcantly lower incidence versus GLIM
Slightly higher incidence with CANA as add-on to MET versus SITA;
similar incidence with CANA as add-on to MET ? SU versus SITA
with greater HbA1c lowering with CANA; incidence with CANA/
MET was similar to MET in initial combination therapy
Low incidence across studies of severe hypoglycemia episodes
Diabetic ketoacidosis AEs Low incidence across studies
No serious AEs of diabetic ketoacidosis with CANA as add-on to MET,
MET ? PIO, or in the MET ? insulin subset of CANVAS
1 serious event each with CANA 100 mg as add-on to MET ? SU and
with CANA 300 mg as initial combination therapy
Fractures Incidence low and similar across studies in non-CANVAS studies
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canagliflozin in combination with metformin
was associated with a transient reduction in
eGFR that attenuated over time [16, 24–30].
CANAGLIFLOZIN/METFORMIN FDC
PLACE IN THERAPY
Guidelines for treating patients with T2DM
emphasize a personalized approach for
improving glycemic control to minimize
diabetes-related complications and drug-related
side effects [1, 2]. Metformin is typically used as a
first-line pharmacotherapy for patients with
T2DM [1, 2]. However, for patients unable to
attain glycemic control with metformin alone,
the selection of additional AHAs is warranted. In
newly diagnosed patients with high initial
HbA1c levels, an initial combination approach
consisting of therapies with complementary
mechanisms of action is recommended [1, 2].
The use of an FDC can simplify combination
treatment compared to two-pill administration
and can potentially provide increased therapy
adherence and reduced medication errors
[34–40]. In addition, FDC therapies with
variable dosing may provide for faster and
greater efficacy with lower risk of AEs compared
withmonotherapy. FDCmedications that donot
directly increase the risk of hypoglycemia and do
not cause weight gain, and preferably cause
weight loss, may lead to increased compliance,
reduced hospitalization, and better cardiorenal
outcomes by reducingmetabolic risk factors [34].
The AACE T2DM disease management
algorithm recommends SGLT2 inhibitors as
the first orally administered add-on therapy to
metformin [1]; thus, an FDC of the SGLT2
inhibitor canagliflozin with metformin may be
valuable for many patients. Results from
phase 3 studies in patients with T2DM show
that the combination of canagliflozin plus
metformin, including canagliflozin and
metformin as initial combination therapy,
provides substantial improvements in glycemic
control, along with other benefits including
weight loss and reductions in systolic BP
[16, 24–30]. As canagliflozin 300 mg provided
superior glycemic control to sitagliptin or
glimepiride as add-on to metformin
Table 5 continued
Parameter Combination of CANA 1MET
Fasting plasma lipids Triglycerides were generally reduced across studies
High-density lipoprotein cholesterol and low-density lipoprotein
cholesterol were generally increased across studies
Clinical laboratory parameters Transient reduction in eGFR early in treatment that attenuated over
time
No clinically meaningful changes in alanine aminotransferase, aspartate
aminotransferase, bilirubin, blood urea nitrogen, creatinine, urate, and
hemoglobin
Small changes in serum electrolytes (i.e., potassium, magnesium,
phosphate)
CANA canagliﬂozin, MET metformin, AE adverse event, PBO placebo, SITA sitagliptin, GLIM glimepiride, UTI urinary
tract infection, eGFR estimated glomerular ﬁltration rate, SU sulfonylurea, PIO pioglitazone, CANVAS CANagliﬂozin
cardioVascular Assessment Study
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[24, 25, 30], the canagliflozin/metformin
combination may be a better therapeutic
option than combination therapy with these
other agents. Overall, canagliflozin in
combination with metformin with or without
other AHAs was generally well tolerated. These
data support the use of the canagliflozin and
metformin FDC in patients with T2DM.
Canagliflozin also demonstrated efficacy and
safety in patients with T2DM and cardiovascular
disease or chronic kidney disease,manyofwhom
were on background metformin [29, 41, 42]. It
has been hypothesized that canagliflozin may
provide cardiovascular and renoprotective
benefits, which will be assessed in ongoing
outcomes studies, including CANVAS
(ClinicalTrials.gov Identifier: NCT01032629),
CANVAS-R (renal endpoints; NCT01989754),
and Canagliflozin and Renal Events in Diabetes
with Established Nephropathy Clinical
Evaluation (CREDENCE; NCT02065791).
CONCLUSION
Attaining early and sustained glycemic control
can reduce the risk of diabetes-related
complications. For many patients with T2DM,
the use of combination therapies with
metformin may be valuable to help them attain
their individualized glycemic goals. Across phase
3 studies, including as initial combination
therapy in drug-naı¨ve patients, canagliflozin in
combinationwithmetforminprovided favorable
glycemic efficacy and additional benefits of
weight loss, BP reduction, and a low risk of
hypoglycemia. Together, the beneficial efficacy
and favorable safety profiles for canagliflozin in
combination with metformin support the use of
the canagliflozin and metformin FDC as a
therapeutic approach in a broad range of
patients with T2DM.
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